Free Trial

Sage Therapeutics (SAGE) Stock Forecast & Price Target

$12.29
+0.12 (+0.99%)
(As of 07/19/2024 ET)

Sage Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 20 Wall Street analysts who have issued ratings for Sage Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 2 have given a sell rating, 15 have given a hold rating, and 3 have given a buy rating for SAGE.

Consensus Price Target

$34.45
180.31% Upside
High Forecast$294.00
Average Forecast$34.45
Low Forecast$8.00

According to the 20 analysts' twelve-month price targets for Sage Therapeutics, the average price target is $34.45. The highest price target for SAGE is $294.00, while the lowest price target for SAGE is $8.00. The average price target represents a forecasted upside of 180.31% from the current price of $12.29.

TypeCurrent Forecast
7/21/23 to 7/20/24
1 Month Ago
6/21/23 to 6/20/24
3 Months Ago
4/22/23 to 4/21/24
1 Year Ago
7/21/22 to 7/21/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
15 Hold rating(s)
15 Hold rating(s)
13 Hold rating(s)
7 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$34.45$34.80$39.28$52.92
Forecasted Upside180.31% Upside134.76% Upside122.10% Upside27.62% Upside
Get Sage Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

SAGE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SAGE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sage Therapeutics Stock vs. The Competition

TypeSage TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.05
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside180.31% Upside1,426.46% Upside9.99% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/19/2024Mizuho
2 of 5 stars
 Lower TargetNeutral ➝ Neutral$18.00 ➝ $16.00+31.47%
7/12/2024JPMorgan Chase & Co.
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$23.00 ➝ $18.00+52.93%
7/2/2024HC Wainwright
3 of 5 stars
 Reiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00+133.64%
6/28/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
6/11/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$15.00 ➝ $15.00+37.61%
5/29/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Beatty
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/29/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell$8.00-32.94%
4/26/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$28.00 ➝ $19.00+37.38%
4/26/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$22.00 ➝ $18.00+32.06%
4/26/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Perform ➝ Sector Perform$26.00 ➝ $15.00+10.05%
4/26/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$21.00 ➝ $17.00+25.18%
4/18/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Outperform ➝ Sector Outperform$34.00 ➝ $19.00+50.44%
4/18/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$25.00 ➝ $17.00+35.24%
4/18/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$30.00 ➝ $16.00+27.29%
4/17/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$24.00+91.54%
4/17/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$24.00 ➝ $14.00+11.29%
2/28/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$20.00 ➝ $22.00+0.09%
12/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$22.00 ➝ $20.00-6.41%
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$21.00+4.90%
8/7/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$311.00 ➝ $294.00+1,655.22%
5/3/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
1/3/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
11/9/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$43.00 ➝ $40.00+18.91%
11/1/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$41.00+8.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:18 PM ET.

SAGE Forecast - Frequently Asked Questions

What is Sage Therapeutics' forecast for 2024?

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Sage Therapeutics is $34.45, with a high forecast of $294.00 and a low forecast of $8.00.

Should I buy or sell Sage Therapeutics stock right now?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 2 sell ratings, 15 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.

Does Sage Therapeutics's stock price have much upside?

According to analysts, Sage Therapeutics's stock has a predicted upside of 132.47% based on their 12-month stock forecasts.

Has Sage Therapeutics been upgraded by Wall Street analysts recently?

Over the previous 90 days, Sage Therapeutics's stock had 1 upgrade by analysts.

What analysts cover Sage Therapeutics?
Do Wall Street analysts like Sage Therapeutics more than its competitors?

Analysts like Sage Therapeutics less than other "medical" companies. The consensus rating for Sage Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SAGE compares to other companies.


This page (NASDAQ:SAGE) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners